{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:29:15Z","timestamp":1767911355427,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009033","name":"NHS Blood and Transplant","doi-asserted-by":"publisher","award":["09\u201015\u201001\u201003"],"award-info":[{"award-number":["09\u201015\u201001\u201003"]}],"id":[{"id":"10.13039\/100009033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1111\/ajt.14619","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T02:56:58Z","timestamp":1512961018000},"page":"1424-1434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) \u2013 results of a randomized controlled clinical trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Richard","family":"Haynes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Staplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Emberson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parminder K.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul N.","family":"Harden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Friend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1111\/ajt.14619_bib1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1600-6143.2004.00515.x","article-title":"Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant."},{"issue":"24","key":"10.1111\/ajt.14619_bib2","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1111\/ajt.14619_bib3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation."},{"issue":"6","key":"10.1111\/ajt.14619_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/TP.0b013e3181856f39","article-title":"Calcineurin inhibitor sparing in renal transplantation","volume":"86","author":"Ekberg","year":"2008","journal-title":"Transplantation."},{"issue":"25","key":"10.1111\/ajt.14619_bib5","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1111\/ajt.14619_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.14619_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation."},{"issue":"5","key":"10.1111\/ajt.14619_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant."},{"issue":"9768","key":"10.1111\/ajt.14619_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet."},{"issue":"9","key":"10.1111\/ajt.14619_bib10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/01.tp.0000237101.58974.43","article-title":"Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence","volume":"82","author":"Mulay","year":"2006","journal-title":"Transplantation."},{"issue":"9","key":"10.1111\/ajt.14619_bib11","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14619_bib12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.14619_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1111\/ajt.14619_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1111\/ajt.14619_bib15","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ."},{"issue":"8","key":"10.1111\/ajt.14619_bib16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.14619_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/ajt.12572","article-title":"Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study","volume":"14","author":"Sutherland","year":"2014","journal-title":"Am J Transplant."},{"issue":"9955","key":"10.1111\/ajt.14619_bib18","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial","volume":"384","year":"2014","journal-title":"Lancet."},{"issue":"1","key":"10.1111\/ajt.14619_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-1440-2-7","article-title":"Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol","volume":"2","author":"Haynes","year":"2013","journal-title":"Transplantation Res."},{"issue":"1","key":"10.1111\/ajt.14619_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics."},{"issue":"5","key":"10.1111\/ajt.14619_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"J Am Med Assoc."},{"key":"10.1111\/ajt.14619_bib22","series-title":"Multiple imputation for non-response in surveys","author":"Rubin","year":"1987"},{"issue":"1","key":"10.1111\/ajt.14619_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Brit","volume":"35","author":"Peto","year":"1977","journal-title":"J Cancer."},{"issue":"6","key":"10.1111\/ajt.14619_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.1976.220","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Brit","volume":"34","author":"Peto","year":"1976","journal-title":"J Cancer."},{"issue":"12","key":"10.1111\/ajt.14619_bib25","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1111\/ajt.12481","article-title":"Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients","volume":"13","author":"Silva","year":"2013","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.14619_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1111\/ajt.14619_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation."},{"issue":"7","key":"10.1111\/ajt.14619_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/TP.0b013e31822805d7","article-title":"Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal","volume":"92","author":"Heilman","year":"2011","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.14619_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.transproceed.2011.01.033","article-title":"Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study","volume":"43","author":"Pankewycz","year":"2011","journal-title":"Transplantation Proc."},{"issue":"4","key":"10.1111\/ajt.14619_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/TP.0b013e3181613e65","article-title":"Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation","volume":"85","author":"Smith","year":"2008","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.14619_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1600-6143.2011.03505.x","article-title":"Chronic progressive calcineurin nephrotoxicity: an overstated concept","volume":"11","author":"Matas","year":"2011","journal-title":"Am J Transplant."},{"issue":"9117","key":"10.1111\/ajt.14619_bib32","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0140-6736(05)77739-4","article-title":"Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients","volume":"351","author":"Calne","year":"1998","journal-title":"Lancet."},{"issue":"11","key":"10.1111\/ajt.14619_bib33","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14619_bib34","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"10.1111\/ajt.14619_bib35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMc058158","article-title":"Kaposi\u2019s sarcoma after renal transplantation","volume":"353","author":"Gutierrez-Dalmau","year":"2005","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1111\/ajt.14619_bib36","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/ndt\/gfh957","article-title":"Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus","volume":"20","author":"Bumbea","year":"2005","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"10.1111\/ajt.14619_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"mTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"Diekmann","year":"2012","journal-title":"Transplantation Rev."},{"issue":"Suppl 3","key":"10.1111\/ajt.14619_bib38","first-page":"iii47","article-title":"Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation","volume":"19","author":"Fernandez-Fresnedo","year":"2004","journal-title":"Nephrol Dial Transplant."},{"issue":"9753","key":"10.1111\/ajt.14619_bib39","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.14619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.14619","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522095740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522095740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.14619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:20:38Z","timestamp":1761628838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522095740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1600613522095740"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14619","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) \u2013 results of a randomized controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}